Smith & Nephew

Smith & Nephew is a leading medical technology company, operating in around 100 countries globally. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet complex clinical needs, helping healthcare professionals get closer to zero human and economic consequences of wounds, and its 船壳 site manufactures some of the world’s most advanced wound care products. 



尽管在过去20年大量投资由伤口护理行业,15 - 长期慢性伤口的20%,保持了一年后不愈,这几乎没有改变过那段时间。经济成本,以世界上捉襟见肘的医疗保健制度是在长期得不到支持。人力成本和压力对那些生活与非愈合伤口的家庭是巨大的。 

Smith & Nephew’s goal is to equip health care professionals with products that get these wounds healed and people back to life unlimited.



A five-year framework was agreed in July 2016 between Smith & Nephew and the University of 船壳, with a predicted co-investment of £3 million. The aim of the partnership is to drive research into pioneering approaches to advanced wound care. Leading the collaboration on behalf of the ca88 is Professor Matthew Hardman, who brings more than 20 years' experience in the field of skin biology, with a specific focus on wound healing.

The partnership has established a 球队 of experts charged with developing scientific insights and innovative treatments that will benefit patients. Together, the University and Smith & Nephew have created one of the world’s largest Wound Care 研究 Clusters, combining world-leading academia and industry with the aim of developing scientific insights and innovative treatments for advanced wound care.


As part of this investment, five multi-disciplinary PhD studentships are progressing, and there have already been 19 individual research projects. 所有 are examples where the University, through its applied research, is working with Smith & Nephew to develop innovative approaches to wound healing.

Professor Hardman is now regarded as a trusted and influential member of the Smith & Nephew Innovation 球队. The partnership has fed into the development in 船壳 of Smith & Nephew’s 研究 & Development Centre of Excellence for the Global Wound Management Division, which opened enhanced facilities in May 2017, specialising in a number of areas including clinical sciences, engineering, chemistry and microbiology. 

The Smith & Nephew 船壳 R&D hub attracts major funding from within the company, and this recent period of Innovation and 研究 has been Smith & Nephew’s most prolific in the last twenty years or so, with multiple technology platforms in early and late stage development.


Smith & Nephew and the ca88 continue to collaborate on new projects. 

Smith & Nephew actively recruits graduates from the ca88, as well as offering student placements. Over the last five years, Smith & Nephew has nearly trebled the size of the R&D and clinical 球队s at the site and the largest single source of graduate recruitment to Smith & Nephew in Hull is through 船壳 University.

The ca88 has recruited a new Wound Healing lecturer to the Hull York Medical School, and Smith & Nephew were involved in the shortlisting and interviews. Continued investment will consolidate Hull as a leading hub for wound research. In addition, the partnership is exploring the feasibility of Smith & Nephew staff undertaking PhDs at 船壳.

“Our shared goal is to create a rolling programme aimed at changing wound care management across the world, and, as a consequence, change individuals’ lives. I am not aware of any group anywhere that is doing this as well as the ca88. We are thrilled that the University shares our passion for the importance of advancing wound care, translating this into technologies that can be easily used across the world. This partnership is combining the brightest minds with access to the finest R&D facilities with that purpose front of mind. These are exciting days!” 斯图尔特麦金利 Vice President of 研究 & Innovation at Smith & Nephew